Hikma Pharmaceuticals (LON:HIK) Trading Down 14.1% – Here’s Why

Hikma Pharmaceuticals PLC (LON:HIK) shares traded down 14.1% during mid-day trading on Friday . The stock traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares traded hands during trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Wall Street Analyst Weigh In

HIK has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft dropped their price target on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Berenberg Bank decreased their price objective on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating for the company in a report on Thursday, October 16th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,600 target price on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of GBX 2,615.

Hikma Pharmaceuticals Stock Performance

The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The firm has a market cap of £3.42 billion, a P/E ratio of 9.25, a P/E/G ratio of 2.38 and a beta of 0.41. The business has a fifty day simple moving average of GBX 1,734.94 and a 200-day simple moving average of GBX 1,896.07.

Insider Transactions at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Laura Balan Balan bought 3,500 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was acquired at an average price of GBX 1,821 per share, with a total value of £63,735. Also, insider Mazen Darwazah bought 14,000 shares of the stock in a transaction dated Tuesday, September 16th. The shares were acquired at an average price of GBX 1,603 per share, with a total value of £224,420. Company insiders own 17.77% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.